Didactics-Updates to the Treatment of Recurrent Metastatic Cervical Cancer

Video Transcription

Video Summary

In this video, Dr. Meredith Newton, a GYN Oncology Fellow at UNC, discusses the recent updates in the treatment of recurrent and metastatic cervical cancer. She starts by highlighting the global prevalence of cervical cancer and the poor prognosis for patients with recurrent and metastatic disease. Historically, single-agent chemotherapy with cisplatin was used, but its efficacy was limited. In 2014, a study showed that adding Bevacizumab to cisplatin-based doublet chemotherapy improved overall survival. More recently, Pembrolizumab, a PD-1 inhibitor, has been approved for PD-L1 positive tumors in the second-line treatment. Dr. Newton discusses the results of Keynote 826, which showed improved progression-free survival and overall survival with the addition of Pembrolizumab to platinum-based chemotherapy. She also highlights the ANOVA TV-204 trial, which studied Tizotimab, an antibody drug conjugate, in the second-line treatment. Tizotimab showed promising results with an objective response rate of 24% and a longer duration of response compared to other options. Finally, Dr. Newton mentions the EMPOWER Cervical 1 study, which demonstrated the efficacy of Simiplimab, a PD-1 receptor monoclonal antibody, in the second-line treatment of recurrent and metastatic cervical cancer. She concludes by discussing ongoing trials and the potential treatment paradigm using PD-L1 status to guide treatment decisions. No credits were mentioned in the video.

Asset Subtitle

Meredith Newton
December 2021

Keywords

cervical cancer

recurrent

metastatic

chemotherapy

immunotherapy